NCT03862027

Brief Summary

The investigators aim to demonstrate that use of transpulmonary pressure to guide PEEP management is safe in patients with possible elevations of intracranial pressure.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2019

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 1, 2019

Completed
Same day until next milestone

Study Start

First participant enrolled

March 1, 2019

Completed
3 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 4, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 4, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 5, 2019

Completed
2.1 years until next milestone

Results Posted

Study results publicly available

April 1, 2021

Completed
Last Updated

April 27, 2021

Status Verified

September 1, 2020

Enrollment Period

3 days

First QC Date

March 1, 2019

Results QC Date

March 5, 2021

Last Update Submit

April 6, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in ICP Value

    The Intracranial pressure (ICP) value after intervention will be considered equivalent to the ICP before intervention if the 95% upper bound of the change is lower than the non-inferiority margin of 4 mm Hg.

    Within 5 minutes of catheter placement

Secondary Outcomes (2)

  • Change in Cerebral Perfusion Pressure (CPP)

    Immediately before and 5 minutes after ventilator setting change

  • Change in Mean Arterial Pressure

    Immediately before and 5 minutes after ventilator setting change

Study Arms (1)

Esophageal Balloon catheter

EXPERIMENTAL

All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed \> 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.

Device: Esophageal Balloon catheter

Interventions

Pressures \[Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)\] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP. PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O ("Optimal PEEP"). Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP.

Esophageal Balloon catheter

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients (age \>/= 18) admitted to the Neuro ICU of UNC Hospital requiring mechanical ventilation and with ICP monitoring in place.

You may not qualify if:

  • Pneumothorax or pneumomediastinum
  • Life expectancy \< 24 hours or expected to require mechanical ventilation for \< 24 hours
  • Condition that precludes placement of an esophageal balloon \[esophageal or nasopharyngeal pathology preventing insertion of the esophageal balloon catheter (esophageal ulcerations, tumors, diverticulitis, bleeding varices or in patients with sinusitis, epistaxis or recent nasopharyngeal surgery), severe thrombocytopenia (platelet count \< 30) or coagulopathy (INR \> 3 or on oral anticoagulants).
  • Pre-enrollment ICP \> 20 mm Hg
  • Pre-enrollment CPP \< 60 mm Hg
  • Planned change in the external ventricular drain set point during the pre-intervention, intervention or post-intervention periods
  • Incarceration
  • Variation in ICP of \> 2 cm H2O in the hour prior to intervention.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

Location

MeSH Terms

Conditions

Respiratory InsufficiencyIntracranial Hypertension

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Results Point of Contact

Title
Amanda Kovacich, MD
Organization
University of North Carolina at Chapel Hill

Study Officials

  • Shannon Carson, MD

    University of North Carolina, Chapel Hill

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2019

First Posted

March 5, 2019

Study Start

March 1, 2019

Primary Completion

March 4, 2019

Study Completion

March 4, 2019

Last Updated

April 27, 2021

Results First Posted

April 1, 2021

Record last verified: 2020-09

Locations